Increasing research and development activities for treatment of diseases such as cancer, Ebola, rheumatoid arthritis, multiple sclerosis is expected to propel the growth of the market. For instance, in May 2018, National Institute of Health (NIH) initiated clinical phase I study using single monoclonal antibody (mAb114) for the treatment of Ebola at Bethesda, Maryland, U.S. The study is expected to be completed in November 2024.
Browse the Full Report at https://www.coherentmarketinsights.com/ongoing-insight/antibodies-market-2629
Furthermore, in May 2019, the National Cancer Institute developed an antibody, drug conjugate (lorvotuzumab mertansine), for treatment of neuroblastoma in children. This antibody-drug conjugates (lorvotuzumab mertansine) kills the neuroblastoma cells in the children.
Increasing challenges in production of antibodies is expected to hamper the antibodies market growth. For instance, in May 2017, according to the National Center for Biotechnology Information (NCBI), high cost of resources and animal use is a major challenge for production of antibodies, therefore, limited resources and animals are used in the antibodies production process.
Request Sample Copy of This Report: https://www.coherentmarketinsights.com/insight/request-sample/2629
North America is expected to hold dominant position in the antibodies market owing to increasing collaboration and acquisition activities by the market players in the region. For instance, in January 2019, Integral Molecular, Inc (headquartered in Philadelphia, U.S.) collaborated with Ono Pharmaceutical Co., LTD (headquartered in Osaka, Japan). Integral Molecular is a leader in the discovery of monoclonal antibodies. As part of the collaboration, Integral Molecular provided a platform to Ono pharmaceuticals for discovery of monoclonal antibodies against an undisclosed target.
Furthermore, Asia Pacific is expected to witness significant growth in the antibodies market over the forecast period. Increasing research and development activities are expected to propel growth of the antibodies market in the region. According to GaBI (Generics and Biosimilar Initiative) report, in January 2019, Innovent Company received an approval for two monoclonal antibodies (IB 305 and HLX22) from China’s Food and Drug administration. These monoclonal antibodies are used for treatment of diseases such as lung cancer, breast cancer, glioblastoma, kidney cancer, and ovarian cancer.
Key players operating in the global antibodies market include BioLegend, BETHYL, BIORAD, Enzo, Abnova, Gene Tex, ORIGENE, ROCKLAND antibiotics and assays, Invitrogen by Thermo Fisher Scientific, and ImmuQuest.
Get More Information On This Report: https://www.coherentmarketinsights.com/ongoing-insight/antibodies-market-2629
Subscribe to our newsletter to get notification about new updates,information, discount, etc..